US › Healthcare

GT Biopharma Inc (GTBP)

US · Healthcare · Biotechnology

$0.33+5.67%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-2.8M

Profit YoY

-265.1%

EPS

$-0.11

EPS estimate

$-0.08

EPS came in at -0.11 against a street estimate of -0.08 — a miss of 37.5%.

Key statistics

Market cap

$10.6M

Forward P/E

17.3

P/B

1.40

Book value

$0.21

EPS (TTM)

$-6.46

52-week high

$1.89

52-week low

$0.26

50-day MA

$0.42

200-day MA

$0.53

Beta

0.90

Analyst view

Analysts rate GT Biopharma Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $3.00.

Shareholding

Insiders

5.81%

Institutions

4.22%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	1.02%
Geode Capital Management, LLC	0.66%
Vanguard Fiduciary Trust Co	0.51%
Everhart Financial Group, Inc.	0.23%
SRS Capital Advisors Inc	0.21%
Opal Wealth Advisors, LLC	0.18%
Citadel Advisors Llc	0.15%
Seacrest Wealth Management, LLC	0.11%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for GT Biopharma Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.